Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis.

Leo R. Silberbauer[1,2], Benjamin Eggerstorfer[1,2], Paul Michenthaler[1,2], Sabine Reichel[3], Thomas Stimpfl[3], Thomas Vanicek[1,2], Angela Naderi-Heiden[1,2], Siegfried Kasper[4], Rupert Lanzenberger[1,2], Gregor Gryglewski[1,2*]

[1] Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

[2] Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Austria

[3] Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

[4] Center for Brain Research, Medical University of Vienna, Vienna, Austria

Running title: Oral ketamine for depression

For submission to

medRxiv

Main article		
Word count	295	Abstract
	3998	Main section
Tables: 2, Figures: 2, References: 46		

[*]**Correspondence:**
Gregor Gryglewski, MD, PhD
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria
Waehringer Guertel 18-20, 1090 Vienna, Austria
Telephone: +43 1 40400-35750
E-mail: gregor.gryglewski@muv.ac.at

ABSTRACT

Background: Ketamine represents a significant advancement in antidepressant therapy, but the commonly used intravenous and intranasal application routes currently limit its availability beyond specialized centers. By contrast, oral ketamine treatment might constitute an alternative that is easy to administer with established safety and efficacy for patients with chronic and severe pain at home.

Aims: With this trial we further investigated the evidence on the efficacy and tolerability of oral ketamine as an antidepressant treatment.

Method: 41 patients diagnosed with a moderate to severe depressive episode were randomized to receive either 1mg/kg peroral ketamine or 0.03mg/kg midazolam solution as an active comparator, administered six times over two weeks in a double-blind trial (NCT02992496).

Results While statistical significance for the primary endpoint of MADRS score reduction after one week was not achieved, response rates favored ketamine with a number needed to treat (NNT) of 4.0 (95%-CI: [2.1, 36.2]) at this timepoint. Treatment was well-tolerated, with no serious adverse events reported, potentially due to the lower exposure to ketamine compared to its metabolite norketamine measured in plasma. In a total of 507 patients, meta-analysis of randomized controlled trials on oral ketamine treatment demonstrated its antidepressant efficacy with a NNT = 4.89 (95%-CI: [3.18, 10.54]) for response and a NNT = 6.88 (95%-CI: [4.18, 19.27]) for remission.

Conclusions: Despite that the current trial did not meet its primary endpoint, possibly due to the presence of an active comparator and low immediate side effects, the cumulative evidence up-to-date suggests that oral ketamine treatment leads to relevant improvements in the outcomes of patients with depression. In light of the ease of administration and high tolerability with oral application, this evidence may contribute to removing some of the obstacles that currently restrict the availability of antidepressant treatment with ketamine to high-income areas.

INTRODUCTION

Alleviating the burden of depression remains a major challenge in psychiatry. While there is a wide array of evidence-based treatment options [1], the majority of patients does not respond sufficiently to first-line antidepressant treatment [2]. Ketamine, with its rapid onset of efficacy in difficult to treat cases, constitutes a major advancement in antidepressant therapy as mounting evidence continues to substantiate its efficacy in uni- and bipolar depression [3-6]. After the initial proofs of concept [7, 8], most trials have continued to study the effects of ketamine administered intravenously. The approval of intranasal esketamine by the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment resistant depression (TRD) [9] in 2019 has greatly extended its availability to patients in need. While the intranasal route facilitates drug application, the extensive monitoring of patients required due to side effects such as elevated blood pressure, sedation and dissociative states continues to limit its use to specialized centers [10, 11].

Peroral ketamine administration has proven to be effective in the management of chronic pain across several conditions and self-administration in the home setting was shown to be feasible [12]. After ingestion, ketamine undergoes extensive first-pass metabolism which results in higher levels of metabolites [13] that were previously implicated in its antidepressant effects [14] and might lack adverse effects and abuse potential [15]. Moreover, slow kinetics after oral application may be associated with increased tolerability [16]. The ease of oral ketamine administration may further provide access to treatment for selected patient populations that are not eligible for intravenous or intranasal esketamine treatment, such as patients with uncontrolled arterial hypertension [17] and patients in palliative care settings [18].

To date, several case series and open label studies support the antidepressant effects of oral ketamine treatment [19]. Moreover, oral ketamine was shown to have beneficial effects in the treatment of patients with chronic suicidality [20, 21]. Emerging evidence from randomized, controlled trials is promising, demonstrating the effectiveness of oral ketamine in TRD [22, 23], in accelerating antidepressant response in combination with sertraline [24], and in patients with major depression and chronic pain [25].

The accessibility and low cost of oral ketamine treatment warrants further investigation to substantiate its efficacy and safety across different patient populations and settings. In this randomized, controlled trial, we assessed the rapid efficacy, tolerability and pharmakokinetics of oral ketamine in patients diagnosed with major depressive or bipolar disorder suffering from a moderate to severe depressive episode. A meta-analysis of available randomized controlled trials was performed to contextualize our findings within the broader body of evidence.

METHODS

Participants

Patients were recruited from the in- and outpatient clinics of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna. Patients diagnosed with a moderate to severe depressive episode in the scope of MDD or bipolar disorder were eligible for enrollment. Clinical diagnoses were supported by structured clinical interviews for DSM-IV (SCID-I). Inclusion criteria comprised a 17-item Hamilton Rating Scale for Depression (HDRS) score ≥19 and stable psychopharmacological treatment for at least 10 days. History of psychotic symptoms or substance abuse (except nicotine) were exclusion criteria.

Study design and medication

This trial followed a double-blind, randomized, controlled study design. Participants were randomly assigned to receive either 1mg/kg ketamine (ketamine hydrochloride, Hameln Pharma Plus GmbH) or 0.03mg/kg midazolam (Roche Pharma AG). An active control condition was chosen to optimize blinding and to mitigate the influence of unspecific effects on treatment outcome. Midazolam displays similar pharmacokinetic properties as ketamine and, thus, mimics the time course of its non-specific behavioral effects [26]. The study medication was administered six times over a period of 2 weeks with one or two days between each dose. The blinded study medication was diluted using 5% glucose solution and provided by the hospital pharmacy using syringes containing 10mL solution. Ketamine was provided at a concentration of 10mg/ml and midazolam at a concentration of 0.3mg/ml. One mL per 10kg bodyweight from the prepared solution was transferred to a cup by the study physician. Participants were instructed to ingest the solution at once and were provided with a cup of water after ingestion.

Assessment of antidepressant efficacy

Clinician rated depression severity and antidepressant efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the HDRS. Patient reported outcomes were assessed using the Beck Depression Inventory (BDI). Overall illness severity was assessed using the Clinical Global Impression (CGI) scale. Ratings were performed at baseline (screening), 24 hours after the first dosing and immediately before each subsequent treatment session. Follow-up assessments were performed one and two weeks after the last

administration of the study medication. Efficacy ratings were performed by clinicians who were not involved in the administration of the study medication and the assessment of tolerability.

Assessment of tolerability

Drug effects were assessed using the Clinician Administered Dissociative States Scale (CADSS) [27] and the Altered States of Consciousness Rating Scale (5D-ASC, 11-ASC) 30 minutes after the first dosing [28]. Moreover, visual analog scales (VAS) were performed 30 minutes after the first and last administration to detect the emergence of most common adverse effects as reported by Murrough et al. [29].

Statistical analysis

All statistical analyses were performed using R (v4.0.2, https://www.R-project.org/). Descriptive statistics of demographic and clinical variables were compared between treatment groups. Reduction in MADRS total score one week after start of treatment was the primary endpoint of this study. A linear mixed effects model for repeated measures (baseline, 24 hours, 7 days and 11 days after first dose) was performed using maximum likelihood estimation. The intercept was allowed to vary randomly. Treatment group, time of visit and their interaction were included as fixed effects and subject as random effect.

Secondary end points included the assessment of changes in HDRS, BDI and CGI scores using linear mixed effects models and the comparison of response (≥50% MADRS reduction compared to screening) and remission rates (MADRS <10) between treatment groups. Moreover, safety and tolerability after the first dose as assessed using the CADSS and the ASC were compared between treatment groups using independent two-sided t-tests. Values greater than 1 on the VAS were counted as adverse effects and frequencies between treatment groups after single and repeated dose were compared using Fisher´s exact test.

Meta-analysis of RCTs assessing antidepressant efficacy of oral ketamine

The bibliographic databases PubMed, Scopus, PsycInfo, Web of Science and Google Scholar were systematically searched for randomized controlled trials that assessed the antidepressant efficacy of oral ketamine treatment in depression. The search terms "depression", "MDD", major depressive disorder, "major depressive episode", "oral ketamine", "peroral ketamine" were used. Studies were included if they fulfilled the following inclusion criteria: peer-reviewed English or German language original articles, randomized controlled trials, studies that reported

means and standard deviation values or effect sizes of antidepressant outcome measures. Exclusion criteria were case reports, reviews, meta-analyses and preclinical studies. We included the results of the present trial. Analyses were performed using the metafor package [30]. As the MADRS and the HDRS was utilized to assess antidepressant efficacy across included studies, standardized mean difference (Cohen's d) of the change in depression score between ketamine and control conditions was calculated [31]. Furthermore, meta-analyses based on risk differences (absolute risk reduction) in response and remission rates between treatment groups were calculated and reported as number needed to treat (NNT) for each study. Multilevel random effects models were employed with random effects specified at both the study level and within study level to account for multiple treatment groups within studies. Variance components were estimated using restricted maximum likelihood and the models were used to obtain summary effect sizes.

RESULTS

	Ketamine (n=20)	Midazolam (n=21)
Age (y)	38.0 ± 13.7	42.6 ± 13.2
Sex (f/m)	9/11	9/12
Diagnosis (MDD/BD)	15/5	18/3
MADRS	31.7±3.6	32.0±7.4
$HDRS_{17}$	23.5±3.1	23.7±5.2
BDI	29.8±6.2	29.0±8.8
Current psychopharmacological treatment		
None	2 (10%)	5 (23.8%)
SSRI	7 (35%)	7 (33.3%)
SNRI	8 (40%)	4 (19%)
SARI	3 (15%)	3 (14.3%)
NaSSa	3 (15%)	5 (23.8%)
NDRI	5 (25%)	5 (23.8%)
Tricyclic Antidepressant	2 (10%)	0
Tetracyclic Antidepressant	1 (5%)	0
Mood stabilizer	6 (30%)	5 (23.8%)
Second generation antipsychotic	6 (30%)	6 (28.6%)
Antipsychotic	1 (5%)	2 (9.5%)
Benzodiazepine	4 (20%)	2 (9.5%)
Benzodiazepine on demand	5 (25%)	3 (14.3%)
Antiepileptic drug	5 (25%)	2 (9.5%)
Stimulant	1 (5%)	1 (4.8%)
Other	0	2 (9.5%)

Table 1 Demographics and clinical characteristics of patients (mean ± sd). Groups did not differ in terms of age, sex and baseline depression severity. MDD, Major depressive disorder; BD, Bipolar disorder MADRS, Montgomery-Åsberg Depression Rating Scale; HDRS17, 17-item Hamilton Depression Rating Scale; BDI, Beck Depression Inventory. SSRI, Selective serotonin reuptake inhibitor; SNRI, Serotonin-norepinephrine reuptake inhibitor; SARI, Serotonin antagonist and reuptake inhibitor; NaSSa, Noradrenergic and specific serotonergic antidepressant; NDRI, Norepinephrine-dopamine reuptake inhibitor.

Forty-seven participants met the inclusion criteria and were randomized to treatment groups. Two subjects were lost to follow-up before the first dose, four subjects dropped out during double-blind treatment. 41 patients were included in the primary endpoint analysis. Treatment groups did not differ in terms of age, sex and baseline depression severity (see Table 1).

Antidepressant efficacy

There were numerically higher reductions in depression rating scores in the ketamine compared to the midazolam treatment group, but these did not reach statistical significance at any time point after treatment initiation (24 hours, 7 days or 11 days, all $p > 0.05$, Figure 1). However, we observed a divergence in the number of responders (MADRS reduction $\geq$ 50%) between groups with a number needed to treat (NNT) of 4.0 [2.1, 36.2] after 7 days and 3.4 [1.8, 25.3] after 11 days. There was no significant difference in remission rates between groups.

In 39 patients who completed the final visit, we observed a response rate of 38.5% after two weeks of naturalistic antidepressant treatment that included open-label treatment with peroral treatment in some patients (mean $\pm$ sd MADRS score at final visit = 17.80 $\pm$ 10.47).

Figure 1 a) left: Mean MADRS total score at baseline, 24 hours (1 day), 7 days and 11 days after the first dose of repeated oral ketamine administration are displayed. We did not observe a statistically significant difference between ketamine and midazolam at any timepoint. Error bars indicate the standard error of the mean. b) The proportion of MADRS responders per group at each time point. c) Serial ketamine and metabolite plasma concentration. Median plasma concentration (ng/ml) is shown 20 to 120 minutes after the first dose. Error bars denote median absolute deviation. d) Drug effects on the Altered States of Consciousness Rating Scale (ASC) scale. Mean ($\pm$ standard error of the mean) of the scale's maximum is displayed. Significant differences between ketamine and midazolam were found in "vigilance reduction" and "disembodiment".

Safety and tolerability

30 minutes after the first application, a higher Clinician Administered Dissociative States Scale (CADSS) total score was observed in the ketamine compared to the control group (t=-2.78, p<0.01) (see Table S1). In the ASC a higher vigilance reduction (t=-2.51, p=0.02) and experience of disembodiment (t=-2.36, p=0.03) was observed after ketamine (Figure 1).

Among the items assessed with the VAS 30 minutes after the first study drug administration, more patients in the ketamine group reported dizziness (p<0.01), poor coordination (p<0.05), poor concentration (p<0.01), and anxiety (p<0.05) after the first dose (Table 2). In contrast, the only side effect reported at a higher rate after the last dose of ketamine vs. midazolam was poor coordination (p<0.05).

	First dose			Last dose		
	Midazolam (n=21)	Ketamine (n=22)	p	Midazolam (n=20)	Ketamine (n=19)	p
VAS total score (mean ± SD)	31.47±12.11	46.18±16.70		35.63±9.14	46.61±23.19	
N (%)						
Nausea	1 (4.76)	5 (22.73)	0.19	1 (5.00)	5 (26.32)	0.09
Vomiting	0	0		0	1 (5.26)	0.49
Dry mouth	8 (38.10)	13 (59.09)	0.23	4 (20.00)	9 (47.37)	0.10
Constipation	1 (5.00)#	1 (4.55)	1	1 (5.00)	2 (10.53)	0.61
Diarrhea	0#	1 (4.55)	1	1 (5.00)	1 (5.26)	1
Dizziness	**8 (38.10)**	**18 (81.82)**	**<0.01****	5 (25.00)	11 (57.90)	0.05
Palpitation	3 (14.29)	3 (13.64)	1	4 (20.00)	6 (31.58)	0.48
Chest pain	0	1 (4.55)	1	2 (10.00)	3 (15.79)	0.66
Increased perspiration	3 (14.29)	2 (9.09)	0.66	4 (20.00)	7 (36.84)	0.30
Itching	0	1 (4.55)	1	1 (5.00)	0	1
Dry skin	0#	0		2 (10.00)	4 (21.05)	0.41
Rash	0#	0		0	1 (5.26)	0.49
Headache	3 (15.00)#	7 (31.82)	0.29	6 (30.00)	3 (15.79)	0.45
Poor coordination	**3 (15.00)#**	**12 (54.55)**	**<0.05***	**3 (15.00)**	**9 (47.39)**	**<0.05***
Tremors	0#	2 (9.09)	0.49	0	2 (10.53)	0.23
Blurred vision	4 (20.00)#	9 (40.91)	0.19	4 (20.00)	8 (42.11)	0.18
Ringing in ears /Tinnitus	3 (15.00)#	2 (9.09)	0.66	1 (5.00)	3 (15.80)	0.34
Frequent urination	2 (10.00)#	1 (4.55)	0.60	2 (10.00)	5 (26.32)	0.24

Painful urination	0¶	0		0	0	
Difficulty urinating	0¶	0		0	1 (5.26)	0.49
Poor concentration	**5 (25.00)[#]**	**15 (68.18)**	**<0.01****	5 (25.00)	9 (47.37)	0.19
Restlessness	4 (20.00)[#]	5 (22.73)	1	5 (26.32)[#]	4 (22.22)[#]	1
Anxiety	**1 (5.00)[#]**	**7 (31.82)**	**<0.05***	3 (15.79)[#]	2 (11.11)[#]	1
Decreased Energy	4 (20.00)[#]	7 (31.82)	0.49	8 (42.11)[#]	4 (22.22)[#]	0.30
Fatigue	11 (55.00)[#]	12 (54.55)	1	11 (57.90)[#]	7 (38.89)[#]	0.33
General malaise	3 (15.00)[#]	5 (22.73)	0.70	5 (26.32)[#]	8 (44.44)[#]	0.31

Table 2 Results of the visual analogue scale (VAS) assessing commonly reported side effects as reported by Murrough et al. Counts of more than 1 on the VAS are reported as number of patients and percentages of the total number of patients.*, p<.05; **, p <0.01. [#], Data of one patient is missing; [¶], Data of two patients is missing.

Concentration of ketamine and its metabolites in plasma

The highest median ketamine (median: 34.80 ng/ml; min: 12.9, max: 162.4 ng/ml) plasma concentration was observed 30 minutes after administration. Norketamine was the major metabolite during all timepoints at the day of administration with norketamine concentrations exceeding ketamine concentrations as early as 20 minutes after administration. Median norketamine plasma concentration was highest (median: 290.70 ng/ml; min: 174.7, max: 483.7 ng/ml) 60 minutes after administration. Ketamine concentration was below the quantification threshold in all samples obtained after 24 hours and measured 48 hours after the application of the fifth dose (day 11). Norketamine concentration after 24 hours and 11 days after drug administration was below the quantification threshold in more than 50% of subjects. Dehydronorketamine demonstrated significant instability in blood samples stored at -80 degrees Celsius, rendering results unreliable. Highest median dehydronorketamine concentration was measured at 120 minutes (median: 58.40; min: 19.1, max: 254.1 ng/ml). Results of exploratory analyses including dehydronorketamine are reported in the supplement.

Exploratory analyses

Correlation between CADSS and MADRS reduction

A correlation between the CADSS total score obtained 30 minutes after the first drug administration and MADRS change after seven days (r_s = -0.61, p < 0.01) and after 11 days (r_s = -0.55, p < 0.05) was observed (see Supplemental Figure 2).

Correlation between the ASC and MADRS reduction

Early response:

A significant correlation between MADRS reduction after 24 hours and the dimensions visionary restructuralization ($R = -0.64$, $p = 0.0039$) and auditory alterations ($R = -0.59$, $p = 0.011$) and the subdimensions experience of unity ($R = -0.52$, $p = 0.026$), spiritual experience ($R = -0.52$, $p = 0.028$), blissful state ($R = -0.61$, $p = 0.0073$, insightfulness ($R = -0.56$, $p = 0.015$), impaired control and cognition ($R = -0.49$, $p = 0.041$), complex imagery (-0.69, $p = 0.0017$), audio-visual synesthesia ($R = -0.49$, $p = 0.038$) and changed meaning of percepts ($R = -0.71$, $p = 0.0011$), respectively, was observed.

Late response:

After seven days, a significant correlation between MADRS reduction and the dimensions visionary restructuralization ($R = -0.65$, $p = 0.0027$) and auditory alterations ($R = -0.64$, $p = 0.003$), and the subdimensions experience of unity ($R = -0.46$, $p = 0.045$), spiritual experience ($R = -0.62$, $p = 0.005$), blissful state ($R = -0.67$, $p = 0.0018$), insightfulness ($R = -0.53$, $p = 0.021$), complex imagery ($R = -0.63$, $p = 0.004$), elementary imagery ($R = -0.52$, $p = 0.021$) and audio-visual synesthesia ($R = -0.5$, $p = 0.03$), respectively, was observed.

Correlation between plasma levels and MADRS reduction

No correlation between ketamine and norketamine plasma levels and MADRS reduction was observed (see Supplement for results of dehydronorketamine).

Correlation between plasma levels and tolerability

A significant correlation between the CADSS total score and plasma levels of ketamine ($R = 0.63$, $p = 0.0017$) and norketamine ($R = 0.42$, $p = 0.049$) after 30 minutes and ketamine after 60 minutes ($R = 0.58$, $p = 0.0056$) was observed. Correlations with the mean of plasma levels at 20 and 30 minutes as well as at 60 and 120 minutes, respectively, were calculated for each metabolite to enhance the robustness of the analysis. Significant effects were observed for ketamine at both time points, whereas correlations with norketamine were not significant at either time point.

A correlation between ketamine plasma concentration 20 minutes after administration and the dimension oceanic boundlessness ($R = 0.5$, $p = 0.02$), the subdimension anxiety ($R = 0.51$, $p = 0.018$) and elementary imagery ($R = 0.57$, $p = 0.0069$) and, respectively, ketamine plasma

concentration 30 minutes after administration and the dimensions oceanic boundlessness (R = 0.61, p = 0.0037), anxious ego-dissolution (R = 0.49, p = 0.024), visionary restructuralization (R = 0.49, p = 0.025), the 5D-ASC total score (R = 0.5, p = 0.023) and the 3D-OAV total score (R = 0.49, p = 0.026), the subdimension disembodiment (R = 0.5, p = 0.021), anxiety (R = 0.56, p = 0.0089) and elementary imagery (R = 0.46, p = 0.035) was observed.

Norketamine plasma concentration after 20 minutes correlated with the subdimension elementary imagery (R = 0.46, p = 0.037) and norketamine plasma levels after 30 minutes correlated with the subdimensions disembodiment (R = 0.45, p = 0.039) and anxiety (R = 0.47, p = 0.033).

Meta-analysis of RCTs assessing antidepressant efficacy of oral ketamine

The systematic literature research yielded six eligible RCTs [23-25, 32, 33]. Together with the present investigation the meta-analysis comprised seven studies with a total of 507 patients. The summary effect estimate for differences in depression rating scales between groups after treatment clearly indicated antidepressant efficacy of oral ketamine treatment (standardized mean difference = -0.84; 95% CI: [-1.54, -0.15]). Furthermore, efficacy was evident with regard to differences in the number of responders between treatment groups. The NNT estimated by meta-analysis was 4.89 (95% CI: [3.18, 10.54]) for response and 6.88 (95% CI: [4.18, 19.27]) for remission (Figure 2)

Figure 2. Antidepressant efficacy of peroral ketamine treatment in depression. Top panel: A forest plot summarizing the differences in depression rating scores between groups receiving ketamine versus control treatments, yielding an effect size of -0.84 (95% CI: [-1.54, -0.15]). Bottom panel: Forest plots illustrating the number needed to treat (NNT) for response (left) and remission (right). The NNT for response is 4.89 (95% CI: [3.18, 10.54]), while the NNT for remission is 6.88 (95% CI: [4.18, 19.27]).

DISCUSSION

Main findings

This randomized controlled trial assessed the efficacy and tolerability of repeated oral ketamine in patients suffering from depression. While the primary endpoint of differences in MADRS scores between treatment groups after 7 days was not significant, we observed a higher response rate after oral ketamine when compared to the active control midazolam. Oral ketamine was well tolerated and occurring side effects were mild and transient.

Our meta-analysis of randomized controlled trials comprising a total of 507 patients demonstrated antidepressant efficacy of oral ketamine treatment.

Antidepressant efficacy

Evidence on antidepressant efficacy of oral ketamine is currently limited and, so far, only one randomized controlled study demonstrated antidepressant efficacy of repeated oral ketamine in a study design that directly compares to the present investigation [23]. The reported mean reduction of ~10 points on the MADRS score after 14 days is consistent with our results (mean reduction after 11 days: 9.95). The longer observation period and a lower response rate in the control group in the study by *Domany et al.* may help reconcile the differences observed in comparison to our study. In the trial by *Jafarinia et al.*, oral ketamine was compared to the analgesic diclofenac in depressed patients with chronic pain [25]. A statistically significant effect of ketamine treatment was reported after a period of six weeks, an observational period that lies beyond the scope of our study. Moreover, results may be confounded by analgesic effects of ketamine. Add-on treatment of daily oral ketamine to a newly initiated selective serotonin reuptake inhibitor accelerated treatment response in the RCT by *Arabzadeh and colleagues [24]*. Patients in our study, in contrast, received stable psychopharmacological treatment for two weeks and ketamine was administered less frequently. Our findings align with recent data from RCTs showing a positive but non-significant trend for antidepressant efficacy of low-dose peroral ketamine [32, 33]. Both trials suggest that higher doses or optimized dosing strategies may enhance clinical outcomes. Promising results were recently reported by *Glue et al.* using an extended-release oral ketamine formulation in a TRD population [34]. Their use of an enrichment design successfully addressed the challenge to separate clinical response between groups as observed in our trial. In contrast to previous RCTs, an active control condition, i.e. midazolam, was used in our study. Maintaining the blind is a key challenge in ketamine trials given its unambiguous subjective effects. Midazolam, frequently used as a control condition in studies demonstrating antidepressant efficacy of intravenous ketamine,

offers comparable pharmacokinetics and behavioral effects [5, 26]. The placebo effect in depression trials is known to be large [35] and greater improvement in depression severity following midazolam vs. saline and resulting smaller effect sizes for ketamine were shown [36]. Thus, the use of midazolam as an active control may have prevented our results from reaching statistical significance. However, the observed mean reduction in MADRS (from 6.07 after 24 hours to 9.95 after 11 days) aligns with previously reported treatment effects in positive ketamine trials using intravenous and oral administration, respectively, and can be considered as clinically meaningful [5, 23, 37]. However, our findings are also in line with recent reports of low effect sizes observed in studies successfully masking treatment allocation through surgical anesthesia [38]. Clinical baseline characteristics, such as high anxiety levels (12 patients with anxious depression in the midazolam group vs. 10 in the ketamine group according to the HDRS anxiety-somatization factor), and patients expectancy may have contributed to the large response in the midazolam group. In sum, the study designs of previous RCTs were highly heterogeneous and, consequently, we conducted a meta-analysis incorporating previously published RCTs in order to contextualize our results within this diverse data landscape. Our results strongly support antidepressant efficacy of oral ketamine treatment in terms of symptom reduction as well as differences in response and remission rates between treatment groups. Consequently, we argue that oral ketamine treatment may represent a viable option for the treatment of depression.

Tolerability

Besides its antidepressant effects, oral ketamine treatment was consistently shown to be well tolerated and safe. The occurrence of adverse events associated with oral ketamine treatment was assessed using standardized questionnaires commonly applied in clinical ketamine trials. Ketamine is known as a dissociative anesthetic and previous studies reported elevation in dissociative measures in the treatment of depression using sub-anesthetic ketamine doses [4, 26]. In our study, statistically significant higher dissociation scores on the CADSS were observed in the ketamine group. However, this increase was modest compared to previous studies using intravenous ketamine [4, 26] and comparable to those reported with intranasal esketamine [39, 40]. The CADSS is the most commonly used scale to assess the severity of dissociation in depression during ketamine treatment, however, it likely underestimates its frequency and does not fully capture the psychotomimetic experiences with ketamine [41]. Evidence on whether dissociation correlates with the immediate or long-lasting antidepressant effects of antidepressants remains inconclusive [9]. In our study, we observed a significant

correlation between MADRS reduction after 7 and 11 days and dissociation after the first drug administration as measured using the CADSS. We observed significant group differences in the domain vigilance reduction and the subscale disembodiment of the ASC between groups. While the original primary domains of the altered states of consciousness scale are considered as unspecific, the new lower order subscales developed by Studerus et al. were shown to better differentiate between drug effects [28]. In line with our results, ketamine induced dissociation is typically captured by the subscale disembodiment [42]. With the majority of subscales ranging below the 10 per cent mark of the scale´s maximum, oral ketamine induced lower scores on the ASC when compared to intravenous drug administration [43, 44] which suggests good tolerability of this formulation. In contrast to previous trials, side effects were assessed quantitatively in a structured manner using an extensive visual analogue scale [23]. All observed side effects were mild and transient. Most commonly, dry mouth, dizziness, poor coordination, poor concentration and fatigue were reported (see Table 2). Importantly, no cumulative effect was observed after repeated dosing. A significant difference after repeated dosing was only observed for one item (poor coordination) suggesting habituation to drug effects. We did not observe lower urinary tract symptoms in our trial. However, given the dose-response relationship between ketamine exposure and these symptoms [45], this potential adverse event should be considered during long-term treatment with oral ketamine, which may require higher doses when compared to intravenous or intranasal formulations.

Dosing and pharmacokinetics

We used a fixed dose of 1mg/kg bodyweight, a dosing regimen that yielded promising results in the trial by *Domany et al.* [23] . The low bioavailability is frequently cited as an impediment to oral ketamine treatment and, indeed, ketamine plasma levels observed in our study were lower than the levels reported in studies following intravenous administration [46]. Peroral administration of ketamine leads to pronounced first-pass metabolism, resulting in norketamine as the primary circulating compound at steady state [12][47]. Formulations with extensive metabolism and lower peak ketamine plasma concentrations including peroral ketamine were demonstrated to be safer and were associated with better tolerability [47, 48]. Despite consensus on the therapeutic range of plasma levels is not yet established [9], plasma levels that were observed in our trial suggest that higher doses may be beneficial during antidepressant treatment with peroral racemic ketamine. Results from the study by *Glue et al.* suggest a dose-response relationship, with significant antidepressant effects observed at doses of 120 mg during the open-label phase and 180 mg in the double-blind phase [34]. While these doses exceed those

used in our study by factors of 1.7 and 2.6 for a person with 70kg bodyweight, respectively, the findings also suggest that relatively low doses of approximately 2 mg/kg may yield a meaningful antidepressant effect.

Implications of peroral ketamine treatment

Peroral ketamine treatment for depression offers promising benefits. Unlike intravenous administration, oral administration simplifies clinical procedures, eliminating the need for intravenous cannulation and, thus, reducing patient time in clinics. While a single intranasal dose of esketamine costs over €550, a full treatment series using oral ketamine in our trial may total less than €10 for an average 70 kg person, making it a highly affordable alternative. However, the potential for abuse necessitates cautious implementation of at-home administration with clear guidelines from healthcare providers and regulators. If carefully managed, peroral ketamine could greatly broaden access to effective depression care within communities.

Strengths and Limitations

To the best of our knowledge, this is the first study to assess antidepressant efficacy of oral ketamine using midazolam as an active comparator [19]. We conducted a comprehensive assessment of antidepressant efficacy and safety, incorporating repeated clinician-rating and self-rating questionnaires. Side effects were systematically evaluated after single and repeated dosing and subjective effects were assessed using diverse tools. Standardized questionnaires enable direct comparison with trials using different routes of administration. Additionally, we present pharmacokinetic data obtained from serial assessments of plasma levels of ketamine and its metabolites. In- and exclusion criteria were chosen to ensure enrollment of a clinically representative population. Subjects with uni- and bipolar depression were enrolled and only minor restrictions with respect to psychiatric and medical comorbidities were made. The heterogenous study population, however, complicates the comparability of our results with studies comprising a strictly selected patient population, such as patients with TRD. Unfortunately, we did not measure patients´ treatment expectancy prior to randomization. Moreover, the relatively short observational period and the lack of long-term follow-up data may be considered as a limitation of our study.

<u>Conclusion</u>

In conclusion, our findings, supported by meta-analytic evidence, provide strong support for antidepressant efficacy and safety of peroral ketamine and highlight the need for future research on optimal dosing and delivery methods.

ACKNOWLEDGEMENTS

We thank Patricia Anna Handschuh, Alim Emre Başaran, Mathis Godber Godbersen, Jakob Felix Unterholzner, Valentin Popper, Marius Hienert and Richard Frey for their medical support.

AUTHORS CONTRIBUTION

SK and RL served as principal investigators. GG, LRS and RL designed the study. GG and LRS performed statistical analyses and drafted the first versions of the manuscript. LRS, BE, PM and TV carried out recruitment and clinical management of participants. SR and TS performed analysis of plasma levels of ketamine and metabolites. Medical supervision of the study was provided by SK and AN. All authors revised the manuscript and approved the contents.

FUNDING INFORMATION

This research was funded in part by the Medical-Scientific Fund of the Mayor of the City of Vienna. LRS and GG were recipients of DOC fellowships of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna.

COMPETING INTEREST

RL received travel grants and/or conference speaker honoraria from Bruker BioSpin within the last three years and investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start- up company BM Health GmbH since 2019. SK received grants/ research support, consulting fees and/or honoraria within the last three years. He received grant/ research support from Lundbeck; he has served as a consultant or on advisory boards for Celegne, IQVIA, Janssen, Lundbeck, Mundipharma, Recordati, Takeda and Schwabe; and he has served on speaker bureaus for Angelini, Aspen Farmaceutica S.A., Janssen, Krka Pharma, Lundbeck, Medichem Pharmaceuticals Inc., Neurax- pharma, OM Pharma, Pierre Fabre, Sanofi, Servier, Schwabe, Sun Pharma. The remaining authors declare no potential conflict of interest with respect to the research, authorship, and/ or publication of this article.

REFERENCES

1. Malhi GS, Mann JJ. Depression. *Lancet* 2018; **392**(10161)**:** 2299-2312.

2. Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A *et al.* Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. *World J Biol Psychiatry* 2019; **20**(6)**:** 427-448.

3. Zarate CA, Jr., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A *et al.* Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biol Psychiatry* 2012; **71**(11)**:** 939-946.

4. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C *et al.* Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). *Molecular psychiatry* 2018.

5. Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A *et al.* Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. *Am J Psychiatry* 2019; **176**(5)**:** 401-409.

6. Saelens J, Gramser A, Watzal V, Zarate CA, Lanzenberger R, Kraus C. Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2024.

7. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS *et al.* Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 2000; **47**(4)**:** 351-354.

8. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA *et al.* A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Archives of general psychiatry* 2006; **63**(8)**:** 856-864.

9. McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M *et al.* Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. *Am J Psychiatry* 2021; **178**(5)**:** 383-399.

10. Kasper S, Cubała WJ, Fagiolini A, Ramos-Quiroga JA, Souery D, Young AH. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. *The World Journal of Biological Psychiatry* 2021; **22**(6)**:** 468-482.

11. Ross EL, Soeteman DI. Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. *Psychiatr Serv* 2020; **71**(10)**:** 988-997.

12. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. *Clin Pharmacokinet* 2016; **55**(9)**:** 1059-1077.

13. Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. *European journal of clinical pharmacology* 2015; **71**(4)**:** 441-447.

14. Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. *Translational psychiatry* 2019; **9**(1)**:** 280.

15. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI *et al.* NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* 2016; **533**(7604)**:** 481-486.

16. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. *Anesthesiology* 1998; **88**(1)**:** 82-88.

17. Silberbauer LR, Bartova L, Papageorgiou K, Lanzenberger R, Kasper S, Winkler D. Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension. *J Clin Psychopharmacol* 2020; **40**(4)**:** 418-420.

18. Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD *et al.* Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. *Journal of palliative medicine* 2013; **16**(8)**:** 958-965.

19. Meshkat S, Haikazian S, Di Vincenzo JD, Fancy F, Johnson D, Chen-Li D *et al.* Oral ketamine for depression: An updated systematic review. *World J Biol Psychiatry* 2023**:** 1-13.

20. Can AT, Hermens DF, Dutton M, Gallay CC, Jensen E, Jones M *et al.* Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study. *Translational psychiatry* 2021; **11**(1)**:** 101.

21. Dutton M, Can AT, Beaudequin D, Jensen E, Jones M, Gallay CC *et al.* Oral ketamine reduces the experience of stress in people with chronic suicidality. *Journal of Affective Disorders* 2022; **300:** 410-417.

22. Kheirabadi D, Kheirabadi GR, Mirlohi Z, Tarrahi MJ, Norbaksh A. Comparison of Rapid Antidepressant and Antisuicidal Effects of Intramuscular Ketamine, Oral Ketamine, and Electroconvulsive Therapy in Patients With Major Depressive Disorder: A Pilot Study. *J Clin Psychopharmacol* 2020; **40**(6)**:** 588-593.

23. Domany Y, Bleich-Cohen M, Tarrasch R, Meidan R, Litvak-Lazar O, Stoppleman N *et al.* Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. *The British journal of psychiatry : the journal of mental science* 2019; **214**(1)**:** 20-26.

24. Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M *et al.* Does oral administration of ketamine accelerate response to treatment in major

depressive disorder? Results of a double-blind controlled trial. *J Affect Disord* 2018; **235:** 236-241.

25. Jafarinia M, Afarideh M, Tafakhori A, Arbabi M, Ghajar A, Noorbala AA *et al.* Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. *J Affect Disord* 2016; **204:** 1-8.

26. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM *et al.* Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. *Am J Psychiatry* 2013; **170**(10)**:** 1134-1142.

27. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS *et al.* Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). *Journal of traumatic stress* 1998; **11**(1)**:** 125-136.

28. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PloS one* 2010; **5**(8)**:** e12412.

29. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS *et al.* Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. *Biol Psychiatry* 2010; **67**(2)**:** 139-145.

30. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of statistical software* 2010; **36:** 1-48.

31. Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. *Psychol Methods* 2002; **7**(1)**:** 105-125.

32. Colla M, Offenhammer B, Scheerer H, Kronenberg G, Vetter S, Mutschler J *et al.* Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results. *Journal of psychiatric research* 2024; **173:** 124-130.

33. Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, Spijker J, van der Meij A, van Asselt ADI *et al.* Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. *Molecular psychiatry* 2024; **29**(9)**:** 2657-2665.

34. Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. *Nat Med* 2024; **30**(7)**:** 2004-2009.

35. Jones BDM, Razza LB, Weissman CR, Karbi J, Vine T, Mulsant LS *et al.* Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2021; **4**(9)**:** e2125531.

36.   Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW *et al.* Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2019; **44**(7)**:** 1233-1238.

37.   Turkoz I, Alphs L, Singh J, Jamieson C, Daly E, Shawi M *et al.* Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. *Acta Psychiatrica Scandinavica* 2021; **143**(3)**:** 253-263.

38.   Lii TR, Smith AE, Flohr JR, Okada RL, Nyongesa CA, Cianfichi LJ *et al.* Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients. *medRxiv* 2023.

39.   Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P *et al.* Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)* 2019; **22**(10)**:** 616-630.

40.   Chen G, Chen L, Zhang Y, Li X, Lane R, Lim P *et al.* Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)* 2022; **25**(4)**:** 269-279.

41.   van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. *J Affect Disord* 2018; **227:** 11-16.

42.   Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine's dissociative and psychedelic properties. *Journal of psychopharmacology (Oxford, England)* 2023; **37**(1)**:** 14-32.

43.   Passie T, Adams HA, Logemann F, Brandt SD, Wiese B, Karst M. Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers. *Eur Neuropsychopharmacol* 2021; **44:** 92-104.

44.   Vidal S, Gex-Fabry M, Bancila V, Michalopoulos G, Warrot D, Jermann F *et al.* Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. *J Clin Psychopharmacol* 2018; **38**(6)**:** 590-597.

45.   Habert J, Katzman MA, Oluboka OJ, McIntyre RS, McIntosh D, MacQueen GM *et al.* Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment. *Prim Care Companion CNS Disord* 2016; **18**(5).

46.   Zarate CA, Jr., Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A *et al.* Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. *Biol Psychiatry* 2012; **72**(4)**:** 331-338.

47.   Glue P, Russell B, Medlicott NJ. Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review. *European journal of clinical pharmacology* 2021; **77**(5)**:** 671-676.

48.   Dutton M, Can AT, Lagopoulos J, Hermens DF. Oral ketamine may offer a solution to the ketamine conundrum. *Psychopharmacology* 2023.